Smoking Cessation > Effectiveness/Harms of Behavior Change on Clinical Outcomes Author: Kumanan Wilson, MD
Editorial changes - 2009-11-18
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Counseling or Intervention on Changing Behavior
Effectiveness/Harms of Behavior Change on Clinical Outcomes
Direct Effectiveness of Intervention/Counseling on Clinical Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines

Tables
References
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
Recommendation
Realize that smoking cessation is associated with dramatic reduction in mortality rates and other adverse outcomes in patients with previous myocardial infarction or documented coronary artery disease.A

Evidence:

  • A meta-analysis of 12 cohort studies of the effect of smoking cessation after myocardial infarction found the combined OR for death in patients who quit was 0.54, equivalent to a number needed to treat of 13 (8).
  • Similar mortality benefits have been seen in persons who quit smoking after coronary artery bypass surgery, after coronary angioplasty, and among patients with angiographically documented coronary stenosis (9; 10; 11; 12).
  • A cohort study of patients post myocardial infarction found that mortality among patients who quit smoking post infarct approached that of nonsmokers within 3 years (13).
  • A randomized trial showed that an intensive smoking cessation intervention targeting smokers hospitalized with acute cardiovascular disease increased abstinence rates (33% intervention vs. 9% usual care) and over a 2-year follow-up period reduced hospitalizations and all-cause mortality (2.8% intervention vs. 12.0% usual care, absolute risk reduction 9.2%, NNT=11) (14).

Comments:

  • None.

FAQs
Edward Ellerbeck, MD, MPH, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Kumanan Wilson, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.